SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation

Fieke W. Hoff, Suleyman Y. Goksu, Naveen Premnath, Prapti A. Patel, Ruth Ikpefan, Gurbakhash Kaur, Madhuri Vusirikala, Taha Bat, Weina Chen, Praveen Ramakrishnan Geethakumari, Larry D., Jr Anderson, Farrukh T. Awan, Robert H. Collins, Olga K. Weinberg, Alagarraju Muthukumar, Stephen S. Chung, Yazan F. Madanat

Abstract


Objective. Patients diagnosed with hematologic malignancies are at increased risk for severe SARS-CoV-2 infection. We evaluated the serological IgG response following two doses of the SARS-CoV-2 vaccine in patients with hematologic malignancies.

Methods. Patients treated at UT Southwestern Medical Center with a diagnosis of a myeloid or lymphoid neoplasm were included. SARS-CoV-2 vaccination response was defined as a positive quantifiable spike IgG antibody titer.

Results. Sixty patients were included in the study and 60% were diagnosed with a myeloid neoplasm. The majority (85%) of the patients with a myeloid malignancy and 50% of the patients with a lymphoid malignancy mounted a serological response after receiving two doses of the vaccine.

Conclusion. Vaccination should be offered irrespective of ongoing treatment or active disease. Findings require validation in a larger cohort of patients.


Keywords


SARS-CoV-2 Vaccination; Hematologic Malignancy; Antibody Response

Full Text:

PDF


DOI: http://dx.doi.org/10.5644/ama2006-124.399

Refbacks

  • There are currently no refbacks.


2023 Department of Medical Sciences, Academy of Sciences and Arts of Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina. All rights reserved.
 
The full text of articles published in this journal can be used free of charge for personal and educational purposes while respecting authors and publishers’ copyrights. For commercial purposes no part of this journal may be reproduced without the written permission of the publisher.